<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941781</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-307-102</org_study_id>
    <nct_id>NCT04941781</nct_id>
  </id_info>
  <brief_title>PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-label Study of PIPE-307 to Determine Muscarinic Type I Receptor (M1AChR) Occupancy Parameters by [11C] PIPE-307 PET Imaging in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pipeline Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pipeline Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the&#xD;
      occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, single-center, open-label, adaptive-design study to investigate the&#xD;
      occupancy of brain M1AChR after a single oral dose of PIPE-307 in healthy volunteers by&#xD;
      positron emission tomography (PET) using the radioligand [11C] PIPE-307.&#xD;
&#xD;
      This study will have an adaptive design to adequately evaluate the relationship between&#xD;
      PIPE-307 exposure and brain M1AChR occupancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>M1AChR receptor occupancy as determined by regional total volume of distribution (VT) of [11C] PIPE-307 at 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>PIPE-307</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of [11C] PIPE- 307.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIPE-307</intervention_name>
    <description>Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with [11C] PIPE-307.&#xD;
Subjects will receive an intravenous dose of the radioligand [11C] PIPE-307 prior to PET imaging.</description>
    <arm_group_label>PIPE-307</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Criteria:&#xD;
&#xD;
          -  Normotensive male or female volunteers between 25-65 years old&#xD;
&#xD;
          -  Deemed healthy on the basis of a clinical history, physical examination, ECG, vital&#xD;
             signs, and laboratory tests of blood and urine&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormal findings at the screening assessments&#xD;
&#xD;
          -  Clinically relevant abnormal medical history or concurrent medical condition&#xD;
&#xD;
          -  Acute or chronic illness&#xD;
&#xD;
          -  Contraindications to MRI, CT, PET, or arterial cannulation procedures&#xD;
&#xD;
          -  Significant exposure to research related radiation or other exposure (defined as ICRP&#xD;
             category IIb or no more than 10 mSv)&#xD;
&#xD;
          -  Positive tests for hepatitis B surface antigen (HBsAg) &amp; Hepatitis C virus (HCV)&#xD;
             antibody, human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Smoke more than 10 cigarettes daily&#xD;
&#xD;
          -  Loss of more than 400 mL blood&#xD;
&#xD;
          -  Vital signs or ECGs outside the acceptable range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jules Lee</last_name>
    <phone>415-819-0405</phone>
    <email>jlee@pipeline-tx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Iwashita</last_name>
    <email>jiwashita@pipeline-tx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

